Side-by-side comparison of AI visibility scores, market position, and capabilities
Unlearn.AI raised $50M+ for its digital twin technology that creates AI-generated control arms for clinical trials, reducing placebo group size and accelerating drug development timelines.
Unlearn.AI generates digital twins of clinical trial patients — AI models trained on historical trial data that predict how a specific patient would have responded as a placebo control. By supplementing small placebo control groups with these digital controls, pharmaceutical companies can run trials with fewer placebo patients (or none at all), reducing participant burden, trial costs, and development timelines without sacrificing statistical validity.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.